Minorities wait longer for breast cancer surgery

Key points
- Among young women diagnosed with breast cancer, black and Hispanic patients were more likely to wait weeks for treatment, in a new study from California.
- In another study published concurrently in JAMA Surgery, researchers from the University of Toledo Medical Center found women with early-stage breast cancer had larger tumors at diagnosis, and were more likely to be treated with breast-removing surgery, if they were covered by Medicaid.
- Researchers found treatment delays were also more common among poor women and those without private insurance - and that a woman's chance of surviving at least five years after cancer surgery was lower when it was put off.
- "This study adds to a number of other studies that have also documented treatment delays that are patterned by race or socioeconomic status," said Sam Harper, who has studied racial differences in breast cancer diagnosis and survival at McGill University in Montreal.
Among young women diagnosed with breast cancer, black and Hispanic patients were more likely to wait weeks for treatment, in a new study from California.
Researchers found treatment delays were also more common among poor women and those without private insurance - and that a woman's chance of surviving at least five years after cancer surgery was lower when it was put off.
"This study adds to a number of other studies that have also documented treatment delays that are patterned by race or socioeconomic status," said Sam Harper, who has studied racial differences in breast cancer diagnosis and survival at McGill University in Montreal.
"What the study does identify is that there are differences… the study really can't tell us much about why that's occurring," he told Reuters Health.
For example, Harper said, it's possible minority patients are sicker than whites, on average, and doctors wait to treat them for good reason. Or, poor women may have more trouble taking time off from work and getting to their appointments.
"Of course, there's the potential for discrimination in treatment," said Harper, who wasn't involved in the new research. "I think that's what's most concerning about findings like this."
For their study, Hoda Anton-Culver from the University of California, Irvine, and colleagues analyzed records of 8,860 women age 15 to 39 that were diagnosed with breast cancer in 1997 through 2006. Although cancer is rare in that age group - accounting for 5 to 6 percent of all breast cancers - it's typically more aggressive than in older women, the researchers noted.
They found the time between diagnosis and treatment - whether surgery or chemotherapy - was delayed more than six weeks in 8 percent of white women and 15 percent of both Hispanic and black women.
Likewise, between 9 and 10 percent of privately-insured women had their treatment delayed more than six weeks, compared to 18 percent of those who had no insurance or were covered by Medicaid.
And for women treated with surgery, in particular, outcomes were substantially worse after a long delay: 80 percent of those women lived at least five years after surgery, compared to 90 percent of patients who waited less than two weeks for treatment.
Anton-Culver said younger women are a unique group because they're often in between insurances or in between jobs.
"Our healthcare system does not allow for access to healthcare by all people in the same manner," she told Reuters Health.
"Without having a real standard of care (for type of treatment and time to treatment) that the healthcare system is accountable for, you will see those differences."
DIFFERENCES FOR THOSE ON MEDICAID?
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNeoadjuvant use of pertuzumab in HER2-positive breast cancer
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable…
4 December 2015
NewsPotential new therapy for triple-negative breast cancer shows promise in lab studies
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. In a recent study…
28 October 2015
NewsUGR scientists patent an effective drug for treating breast, colon, and skin cancers
Scientists from the University of Granada (UGR) have patented an effective drug for treating cancer stem cells (CSCs) in breast, colon, and skin cancers. The researchers have proved the anti-tumor effects of the drug on…
21 October 2015



